Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 231 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
Patents for C07D 231 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings (25,550)
11/2007
11/27/2007US7300936 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors
11/27/2007US7300917 Remedy for chronic disease
11/27/2007US7300639 Process for removing metals from liquids
11/27/2007US7300474 For brightening an acrylic fiber; storage stability
11/27/2007US7300469 Dyeing human hair;aqueous solutions
11/22/2007WO2007131538A1 Azepane- or azocane-substituted pyrazoline compounds, their preparation and use as medicaments
11/22/2007WO2006092213A8 Pyrazolylcarboxanilides
11/22/2007US20070270479 New pyrazole derivatives and diabetic medicine containing them
11/22/2007US20070270478 e.g. 3-[4-(3,5-bis-trifluoromethyl-pyrazol-1-yl)-phenyl]-2-(2,3-difluoro-phenyl)-acrylonitrile; immunosuppressant; bioavailability; side effect reduction; interleukin-2 inhibitor
11/22/2007US20070270474 Pyrazole compounds for treatment of neurodegenerative disorders
11/22/2007US20070270427 vascular endothelial growth factor receptor inhibitors such as N2-(3-methyl-1H-indazol-6-yl)-N4-{3-[(methylsulfonyl)methyl]phenyl}-1,3,5-triazine-2,4-diamine trifluoroacetate, used as anticarcinogenic, antitumor or antiproliferative agents
11/22/2007US20070270312 Heteroaroyl-Substituted Serineamides
11/22/2007DE102006023336A1 1,5-Diphenyl-pyrazole II 1,5-diphenyl-pyrazoles II
11/21/2007EP1857459A2 Pyrazolopyrimidine compound and a process for preparing the same
11/21/2007EP1856057A1 Tetrahydroindolone and tetrahydroindazolone derivatives
11/21/2007EP1856056A1 Phenoxy benzamide compounds with utility in the treatment of type 2 diabetes and obesity
11/21/2007EP1856055A1 Pyrazole carboxylic acid anilides, method for the production thereof and agents containing them for controlling pathogenic fungi
11/21/2007EP1856054A1 Pyrazolylcarboxanilides
11/21/2007EP1856053A1 Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
11/21/2007EP1458383B1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
11/21/2007EP1408025B1 3,3-dialkoxy-2-hydroxyiminopropionitriles, process for preparation thereof and process of preparing 5-amino -4-nitrosopyrazoles or salts thereof by the use of the same
11/21/2007CN101076519A Amide compound and thrombopoietin receptor activator
11/21/2007CN101076336A Novel curcumin analogues and uses thereof
11/21/2007CN101074242A Cells accumulation for sphosphonate analogs of HIV protease inhibitor compound and the same compound
11/20/2007US7297710 Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics
11/20/2007CA2300289C A pharmaceutical composition active in reducing production of mcp-1 protein
11/15/2007WO2007131219A2 Cannabinoid receptor antagonists/inverse agonists
11/15/2007WO2007129019A1 Sulfonamide compounds useful as edg receptor modulators
11/15/2007WO2007095050A3 N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
11/15/2007WO2007089291A3 Estrogen receptor modulators
11/15/2007WO2007067836A3 Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors
11/15/2007WO2007056469A3 Certain chemical entities, compositions, and methods
11/15/2007WO2002089799A3 Use of dihydropyrazoles to increase erythropoietin and vasculari zation
11/15/2007US20070265475 Oxidation Reaction Catalyst and Process for Producing a Compound Using the Same
11/15/2007US20070265454 reacting a pyrazole compound with an ethylenically unsaturated group-containing isocyanate compound; no need to use any inert solvent such as toluene or xylene, safety to the human body and environment is excellent and the production processes and equipment can be simplified
11/15/2007US20070265327 For therapy of neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal
11/15/2007US20070265325 Nitro Indazole Derivatives
11/15/2007CA2651385A1 Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
11/14/2007EP1854788A1 Method for producing 1-substituted-3-fluoroalkyl pyrazole-4-carboxylate
11/14/2007EP1854784A1 Activator for peroxisome proliferator activating receptor
11/14/2007EP1853595A1 (1,5-diphenyl-1h-pyrazol-3-yl)oxadiazole derivatives, preparation method thereof and use of same in therapeutics
11/14/2007EP1853590A1 Fused heterocyclic compounds and their use as sirtuin modulators
11/14/2007EP1853565A1 Menthane carboxamide derivatives having cooling properties
11/14/2007EP1853257A2 Pyrazole compounds
11/14/2007EP1509537B9 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such
11/14/2007CN101072767A Method for preparing n-phenylpyrazole-1-carboxamides
11/14/2007CN101072761A 2-alkyl-cycloalk(en)yl-carboxamides
11/14/2007CN101072757A Benzamide derivatives that act upon the glucokinase enzyme
11/14/2007CN101072503A 3-cyclopropyl-4-(3-amino-2-methylbenzoyl)pyrazols and the use of the same as herbicides
11/14/2007CN101070316A Di-aryl acid derivatives as ppar receptor ligands
11/14/2007CN101070305A Process for producing N-phenylpyrazolecarbonitrile
11/14/2007CN100348586C Synthesis of diaryl pyrazoles
11/13/2007US7294645 E.g., N-[[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]methyl]butane-1-sulfonamide and 3-chloro-N-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]methyl]benzenesulfonamide; cannabinoid receptor antagonists
11/13/2007US7294642 1,3-Diamino-2-hydroxypropane pro-drug derivatives
11/13/2007CA2248304C Surface modified carbonate materials
11/13/2007CA2235642C Processes for preparing sildenafil
11/13/2007CA2213080C 1-aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists
11/08/2007WO2007125952A1 Amine derivative having npy y5 receptor antagonist activity
11/08/2007WO2007107470A3 Pyrazoles as 11-beta-hsd-1
11/08/2007US20070260059 Filters for Electronic Display Devices
11/08/2007US20070259934 Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
11/08/2007US20070259925 Dpp iv inhibitors
11/08/2007US20070259920 P2X7, receptor antagonists and uses thereof
11/08/2007US20070259884 4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity
11/08/2007US20070259873 Selective in presence of at least one other cathepsin isozyme; such as N-{-2-[2-(4-methoxy-phenylamino)-ethylcarbamoyl]-cyclohexyl}-3-methyl-benzamide
11/08/2007US20070259863 Arylphenylamino-,Arylphenylamide-, and Arylphenylether-Sulfide Derivatives
11/08/2007US20070259208 Electroluminescent materials and devices
11/08/2007US20070258929 4-(Pyrazol-4-ylimino)-2,5-cyclohexadienylidene quaternary ammonium salts; oxidation color dyes, pyrazole dyes, and hair dyes; intense blue; colorfastness, washfastness, storage stability, water solubility
11/08/2007CA2650683A1 Amine derivative having npy y5 receptor antagonist activity
11/07/2007EP1852431A1 Optically active tetrahydronaphthalene derivative
11/07/2007EP1851210A2 Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments
11/07/2007EP1851204A1 Naphthalene derivatives as modulators of the glucocorticoid receptor
11/07/2007EP1851199A1 Substituted bis aryl and heteroaryl compounds as selective 5ht2a antagonists
11/07/2007EP1087941B9 Thiolesters and uses thereof
11/07/2007CN101068887A Pyrazole azomethines and colorants containing these compounds
11/07/2007CN101068772A N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
11/07/2007CN101066950A 4-amino-5-methylpyrazole derivatives and process for production thereof
11/07/2007CN100347158C Bicyclic compound
11/06/2007USRE39916 Compounds that modulate PPAR activity and methods for their preparation
11/06/2007US7291744 N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
11/06/2007US7291637 4,7-Methano--, ethano-, oxy- or thio- indazol-3-ones or benzisothiazol-3-ones in which the S is mono- or dioxygenated, e.g., 3a,4,7,7a-tetrahydro-4,7-methano-1,2-benzisothiazol-3(2H)-one-1,1-dioxide; treatment of diseases such as cancer and immune disorders
11/01/2007WO2007123855A2 Pyrazolines for controlling invertebrate pests
11/01/2007WO2007122440A1 Process for the preparation of fipronil, an insecticide, and related pyrazoles
11/01/2007WO2007122165A1 Novel compounds
11/01/2007WO2007121687A1 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
11/01/2007WO2007121578A1 Indole amide derivatives as ep4 receptor antagonists
11/01/2007WO2007098967A3 Imidazole compounds having pharmaceutical activity towards the sigma receptor
11/01/2007WO2007061923A3 Glucokinase activators
11/01/2007US20070254937 Thienopyrazoles
11/01/2007US20070254935 Pyrazole and imidazole compounds and uses thereof
11/01/2007US20070254929 Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
11/01/2007CA2649509A1 Novel compounds
11/01/2007CA2648729A1 Indole amide derivatives as ep4 receptor antagonists
10/2007
10/31/2007EP1849776A1 Azepane- or Azocane-substituted pyrazoline compounds, their preparation and use as medicaments
10/31/2007EP1849775A1 Cycloalkane-substituted pyrazoline compounds, their preparation and use as medicaments
10/31/2007EP1848694A1 Heterocyclic substituted phenyl methanones as inhibitors of the glycine transporter 1
10/31/2007EP1848428A2 Thiazole amides, imidazole amides and related analogues
10/31/2007EP1144384B1 Compounds which inhibit leukocyte adhesion mediated by vla-4
10/31/2007EP1063227B1 Hydrazide fixed to resin and derivative thereof, and method for synthesizing pyrazolones in solid phase
10/31/2007EP0910564B1 D-amino acid derived inhibitors of cysteine and serine proteases
1 ... 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 ... 256